BLU-924 — Investigational Agent
KRAS Inhibitor · Phase 1/2 · Blueprint Medicines
Mechanism of Action
BLU-924 (SAR449336) is an investigational pan-KRAS inhibitor targeting a spectrum of oncogenic KRAS mutations to suppress constitutive RAS-driven proliferation. It is being studied across KRAS-mutant solid tumors including pancreatic and colorectal cancers.
Investigational Indications
- KRAS-mutant pancreatic ductal adenocarcinoma
- KRAS-mutant colorectal cancer
- KRAS-mutant non-small cell lung cancer